171.86
price up icon0.51%   0.88
 
loading
Schlusskurs vom Vortag:
$170.98
Offen:
$171.22
24-Stunden-Volumen:
1.52M
Relative Volume:
1.12
Marktkapitalisierung:
$22.56B
Einnahmen:
$1.53B
Nettoeinkommen (Verlust:
$-214.69M
KGV:
-97.65
EPS:
-1.76
Netto-Cashflow:
$-43.68M
1W Leistung:
+3.94%
1M Leistung:
+11.21%
6M Leistung:
+6.17%
1J Leistung:
+60.32%
1-Tages-Spanne:
Value
$169.90
$173.50
1-Wochen-Bereich:
Value
$162.00
$173.50
52-Wochen-Spanne:
Value
$92.14
$183.00

Natera Inc Stock (NTRA) Company Profile

Name
Firmenname
Natera Inc
Name
Telefon
650-249-9090
Name
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Name
Mitarbeiter
4,434
Name
Twitter
@nateragenetics
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
NTRA's Discussions on Twitter

Vergleichen Sie NTRA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
NTRA
Natera Inc
171.86 22.56B 1.53B -214.69M -43.68M -1.76
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
397.88 156.49B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
196.39 145.01B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
523.92 42.30B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
115.56 34.24B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
154.73 27.64B 15.50B 1.33B 2.16B 7.34

Natera Inc Stock (NTRA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-13 Eingeleitet RBC Capital Mkts Outperform
2025-01-23 Eingeleitet Barclays Overweight
2024-06-03 Fortgesetzt Jefferies Buy
2024-04-08 Fortgesetzt Craig Hallum Buy
2024-02-20 Herabstufung Raymond James Strong Buy → Outperform
2023-12-29 Bestätigt BTIG Research Buy
2023-12-14 Eingeleitet Guggenheim Buy
2023-12-13 Eingeleitet Wolfe Research Outperform
2023-11-13 Hochstufung Raymond James Outperform → Strong Buy
2023-09-28 Eingeleitet Bernstein Mkt Perform
2023-07-05 Fortgesetzt JP Morgan Overweight
2023-05-05 Eingeleitet UBS Buy
2023-01-18 Hochstufung Raymond James Mkt Perform → Outperform
2022-08-25 Eingeleitet Credit Suisse Outperform
2022-04-25 Eingeleitet Stephens Overweight
2022-03-08 Eingeleitet Goldman Buy
2022-01-06 Fortgesetzt Piper Sandler Overweight
2021-10-15 Fortgesetzt Cowen Outperform
2021-06-15 Eingeleitet Raymond James Mkt Perform
2021-05-25 Eingeleitet Wells Fargo Overweight
2021-01-28 Eingeleitet Truist Buy
2020-10-08 Eingeleitet BTIG Research Buy
2020-09-28 Eingeleitet Morgan Stanley Overweight
2020-09-17 Eingeleitet SVB Leerink Outperform
2020-06-10 Fortgesetzt Piper Sandler Overweight
2020-05-07 Hochstufung JP Morgan Neutral → Overweight
2018-10-05 Eingeleitet JP Morgan Neutral
2018-07-05 Bestätigt Piper Jaffray Overweight
2017-08-07 Bestätigt Morgan Stanley Overweight
2016-11-10 Bestätigt The Benchmark Company Buy
2016-05-23 Bestätigt The Benchmark Company Buy
2016-05-11 Bestätigt The Benchmark Company Buy
2016-04-19 Eingeleitet The Benchmark Company Buy
2015-09-28 Hochstufung Wedbush Neutral → Outperform
2015-08-14 Hochstufung Morgan Stanley Equal-Weight → Overweight
2015-08-04 Eingeleitet Robert W. Baird Outperform
2015-07-27 Eingeleitet Morgan Stanley Equal-Weight
2015-07-27 Eingeleitet Piper Jaffray Overweight
2015-07-27 Eingeleitet Wedbush Neutral
Alle ansehen

Natera Inc Aktie (NTRA) Neueste Nachrichten

pulisher
Jun 18, 2025

Natera Approves Equity Plan Amendment at Annual Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

DNA Testing Market Size, Share, and Forecast 2025-2033: Key - openPR.com

Jun 18, 2025
pulisher
Jun 17, 2025

Natera: Growth Likely To Moderate, Despite Signatera Test Medicare Coverage (NASDAQ:NTRA) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 16, 2025

Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Where are the Opportunities in (NTRA) - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 13, 2025

Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years - Benzinga

Jun 13, 2025
pulisher
Jun 12, 2025

Insider Sell: Gail Marcus Sells 4,000 Shares of Natera Inc (NTRA) - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.

Jun 12, 2025
pulisher
Jun 10, 2025

NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

Transcript : Natera, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Prenatal Genetic Counselling Market 2025-2032: Top Trends & - openPR.com

Jun 10, 2025
pulisher
Jun 09, 2025

Natera at Goldman Sachs Conference: Strategic Growth and Expansion - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Natera at Goldman Sachs Conference: Strategic Growth and Expansion By Investing.com - Investing.com India

Jun 09, 2025
pulisher
Jun 05, 2025

Insider Sell: Steven Chapman Sells Shares of Natera Inc (NTRA) - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Colorectal Cancer Diagnostics Market Size To Boom with Top Key - openPR.com

Jun 05, 2025
pulisher
Jun 05, 2025

Natera stock gains after Leerink Partners reiterates outperform rating By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Natera's Signatera test to be covered under Medicare - MSN

Jun 05, 2025
pulisher
Jun 04, 2025

Medicare expands coverage for Natera’s Signatera MRD test By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Sector Update: Health Care - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Natera Inc (NTRA) Trading 4.28% Higher on Jun 4 - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Natera (NTRA) Gains Medicare Coverage for Genome-Based Cancer Te - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Natera stock gains after Leerink Partners reiterates outperform rating - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Natera's Signatera test to be covered under Medicare (NTRA:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Natera, Inc. Announces Medicare Coverage for Signatera Genome - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Natera (NTRA) Secures Medicare Coverage for Signatera MRD Assay | NTRA Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Natera announces Medicare coverage for Signatera MRD assay - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Medicare expands coverage for Natera’s Signatera MRD test - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Natera Announces Medicare Coverage for Signatera™ Genome | NTRA Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Natera Announces Medicare Coverage for Signatera ™ Genome - Business Wire

Jun 04, 2025
pulisher
Jun 04, 2025

Natera Announces Medicare Coverage for Signatera™ Genome - New Castle News

Jun 04, 2025
pulisher
Jun 03, 2025

Natera (NasdaqGS:NTRA) Showcases 94% Sensitivity In Pan-Cancer Signatera Genome Study - simplywall.st

Jun 03, 2025
pulisher
Jun 02, 2025

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025 - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

Natera Inc.: Is The Recent Growth in Signatera Volumes Here To Stay? - Smartkarma

May 31, 2025
pulisher
May 27, 2025

Natera Inc (NTRA) Shares Up 3.07% on May 27 - GuruFocus

May 27, 2025
pulisher
May 26, 2025

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga

May 26, 2025
pulisher
May 24, 2025

When the Price of (NTRA) Talks, People Listen - news.stocktradersdaily.com

May 24, 2025
pulisher
May 23, 2025

Natera Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily

May 23, 2025
pulisher
May 22, 2025

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting | NTRA Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Natera raises 2025 revenue outlook to $1.94B-$2.02B with 26% growth target - MSN

May 22, 2025
pulisher
May 22, 2025

Transcript : Natera, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 10 - marketscreener.com

May 22, 2025
pulisher
May 19, 2025

Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN

May 19, 2025
pulisher
May 19, 2025

Stocks Showing Rising Market Leadership: Natera Earns 82 RS Rating - Investor's Business Daily

May 19, 2025
pulisher
May 18, 2025

There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price - simplywall.st

May 18, 2025
pulisher
May 17, 2025

Natera (NASDAQ:NTRA) Rating Lowered to “Sell” at StockNews.com - Defense World

May 17, 2025
pulisher
May 17, 2025

Natera (NASDAQ:NTRA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World

May 17, 2025
pulisher
May 16, 2025

Natera: The Clues In Q1 Earnings (NASDAQ:NTRA) - Seeking Alpha

May 16, 2025
pulisher
May 15, 2025

NTRA: Piper Sandler Raises Price Target for Natera | NTRA Stock News - GuruFocus

May 15, 2025

Finanzdaten der Natera Inc-Aktie (NTRA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Natera Inc-Aktie (NTRA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Rabinowitz Matthew
EXECUTIVE CHAIRMAN
May 28 '25
Sale
161.00
10,000
1,610,000
35,000
Rabinowitz Matthew
EXECUTIVE CHAIRMAN
May 20 '25
Sale
153.90
10,000
1,539,000
45,000
Rabinowitz Matthew
EXECUTIVE CHAIRMAN
May 15 '25
Sale
150.20
10,000
1,502,000
74,000
Rabinowitz Matthew
EXECUTIVE CHAIRMAN
Jun 13 '25
Sale
165.85
5,000
829,250
30,000
Sheena Jonathan
CO-FOUNDER
Jun 18 '25
Sale
167.29
3,070
513,571
248,774
Sheena Jonathan
CO-FOUNDER
Jun 16 '25
Sale
164.55
3,000
493,649
37,282
diagnostics_research LH
$261.88
price up icon 0.19%
diagnostics_research WAT
$342.63
price up icon 0.96%
diagnostics_research MTD
$1,153.93
price up icon 0.74%
diagnostics_research DGX
$179.43
price down icon 0.19%
diagnostics_research IQV
$154.73
price up icon 0.08%
Kapitalisierung:     |  Volumen (24h):